Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)
SAN DIEGO, CA – Februry 6, 2018 — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the first patient has completed the first cycle of dosing with PCM-075 in combination with low-dose cytarabine in its Phase 1b/2 multicenter trial of patients with Acute Myeloid Leukemia (AML). Two clinical trial sites are currently screening and enrolling patients and five additional sites are planned to be activated by the end of the first quarter. PCM-075 is the first oral PLK1-selective adenosine triphosphate competitive inhibitor to enter clinical trials with proven antitumor activity in hematologic and solid tumor preclinical models. Read the complete Press Release Here
“We are excited to be leading off the clinical evaluation of PCM-075, a potential new treatment
option for patients with Acute Myeloid Leukemia,” said Alex Spira, M.D., Principal Investigator,
Virginia Canceer Specialists, in Fairfax, Virgnia. “Our initial patient enrolled in the Phase 1b/2
trial completed his first cycle of treatment with PCM-075 in combination with low-dose
cytarabine, and we are pleased with how well this patient tolerated the combination regimen.”
